NBIX News and Press, Neurocrine Biosciences Inc. From 02/10/24

2024-02-10 20:30:24 ET Summary Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntingto...

2024-02-08 16:30:05 ET Summary Today, we focused on Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological disorders. The company has experienced "setbacks" in recent trials, but its primary drug candidate, XEN110...

2024-02-07 12:58:06 ET Neurocrine Biosciences Inc. (NBIX) Q4 2023 Earnings Conference Call February 7, 2024 8:00 am ET Company Participants Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer ...

2024-02-07 07:01:21 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Neurocrine Biosciences Q4 2023 Earnings Preview Bristol-Karuna deal: What other biotechs might be in M&A crosshairs? Seeking Alpha’s Quant Rating on Neur...

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 PR Newswire INGREZZA ® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion , Represen...

Penske Automotive Group Inc. (PAG) is expected to report $3.66 for Q4 2023 Copa Holdings S.A. Class A (CPA) is expected to report $3.9 for Q4 2023 Wynn Resorts Limited (WYNN) is expected to report $1.12 for Q4 2023 U-Haul Holding Co Com (UHAL) is expected to report $0.82 for Q3 2024 ...

2024-02-06 13:15:43 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Bristol-Karuna deal: What other biotechs might be in M&A crosshairs? Citi starts Neurocrine at neutral, sees stock as fairly valued Seeking Alpha’s Quant...

2024-01-28 12:00:53 ET More on Amgen, Vertex Pharma, etc. Biotech And Pharma Diversification Pays Off Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar...

2024-01-23 09:45:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for NBIX on January 23, 2024 10:00AM ET. The previous analyst recommendation was Underperform. NBIX was trading at $140.505 at issue of the analyst recommendation. The overall analyst consensus...

2024-01-23 09:45:02 ET Wells Fargo analyst issues MARKET PERFORM recommendation for NBIX on January 23, 2024 10:00AM ET. The previous analyst recommendation was Market Perform. NBIX was trading at $140.505 at issue of the analyst recommendation. The overall analyst conse...